Relationship between gonadotropin releasing hormone agonist dosage and in vitro fertilization outcome

Gynecological Endocrinology

Volumn 18, Issue 2, 2004, Pages 69-73

  Lorusso, F ^a   Depalo, R ^a   Selvaggi, L ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Body Mass Index; GnRH Agonist; In vitro Fertilization

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; TRIPTORELIN; TRYTORELIN ACETATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; HYPOPHYSIS; MAJOR CLINICAL STUDY; OOCYTE; OOCYTE CLEAVAGE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; OOCYTES; OVULATION INDUCTION; PROSPECTIVE STUDIES; TRIPTORELIN;

EID: 1342284375     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590310001651830     Document Type: Article

References (18)

1. Roest J, van Heusden AM, Mous H, et al. The ovarian response as a predictor for successful in vitro fertilization treatment after the age of 40 years. Fertil Steril 1996;66:969-73
2. Dodson WC. Role of gonadotropin releasing hormone agonists in ovulation induction. J Reprod Med 1989;34(1 Suppl):76-80
3. Dodson WC, Hughes CL, Whitesides DB, et al. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1987; 65:95-100
4. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2002;(3):CD002808
5. Marcus SF, Ledger WL. Efficacy and safety of long-acting GnRH agonists in in vitro fertilization and embryo transfer. Hum Fertile (Camb) 2001;4:85-93
6. Loveland JB, McClamrock HD, Malinow AM, et al. Increased body mass index has a deleterious effect on in vitro fertilization outcome. J Assist Reprod Genet 2001;18:382-6
7. Wittemer C, Ohl J, Bailly M, et al. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000;17:547-52
8. Lashen H, Ledger W, Bernal AL, et al. Extremes of body mass do not adversely affect the outcome of superovulation and in vitro fertilization. Hum Reprod 1999;14:712-15
9. Dechaud H, Ferron G, Anahory T, et al. Obesity and assisted reproduction techniques. Contracept Fertile Sex 1998;26:564-7
10. Hanssens RM, Brus L, Cahill DJ, et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6:505-18
11. Kang SK, Choi KC, Cheng KW, et al. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 2000;141:72-80
12. Deslypere JP, Verdonick L, Vermeleun A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 1985;61:564-70
13. Dumesic DA, Matteri RL. Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot. Int J Fertil 1993; 38:139-46
14. Hansen LM, Batzer FR, Corson SL, et al. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens. J Reprod Med 1997; 42:247-50
15. Zullo F, Di Carlo C, Pellicano M, et al. Superovulation with human follicle stimulating hormone: correlation with body mass index and body fat distribution. Gynecol Endocrinol 1996;10:17-21
16. Shoham Z, Schachter M, Loumaye E, et al. The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995;64:237-51
17. Laml T, Obruca A, Fischl F, et al. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropinic women. Gynecol Endocrinol 1999;13:98-103
18. Wang PT, Lee RK, Su JT, et al. Cessation of low-dose gonadotropins releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders. J Assist Reprod Genet 2002;19:1-6